Market news
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target. Analysts link these updated targets to new PermeaDerm-I data, RECELL usage trends, reimbursement developments and changes to the Stedical agreements, as they reassess how AVITA Medical might scale its burn care portfolio. As you read on, you will see how these moving targets fit into the broader narrative and what to watch to stay...
RCEL outlook: more predictable RECELL reimbursement, RECELL GO rollout, PermeaDerm economics, and Q4 2026 breakeven target.
Avita Medical (NASDAQ:RCEL) presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft. During a key opinion leader webinar, the company
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements f
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets. Presid
Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference. Vance, who has been CEO for about 10 months after previously serving
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026. AVITA Medical President and CEO Cary Vance will be speaking on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available under the Invest
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results. President and Chief Executive Officer Cary Vance said the company’s U.S. RE
Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
AVITA Medical Inc (AVHHL) raises full-year 2026 revenue guidance to $86-$89 million and expects cash flow breakeven by Q4.
Motley Fool Press Release.
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Q2 net revenue grew 18% year over year and 13% sequentially quarter-over-quarter to a record $21.7 million Revenue growth driven by continued execution across the
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings came out
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.
Detailed price information for Elevance Health Inc (ELV-N) from The Globe and Mail including charting and trades.
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 7, 2026, at 6:30 a.m. Au
AVITA Medical’s fair value estimate has been reset from US$6.98 to US$9.00 per share, giving investors a fresh reference point for how analysts are framing the stock today. Behind this change, recent commentary highlights optimism around RECELL adoption, revenue momentum, and cash flexibility, while also flagging that execution against guidance and liquidity remain key watchpoints. As you read on, you will see how these shifting pieces of the AVITA Medical story fit together and what to watch...
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
This is the newest page. Registered accounts read further back.